Official Title Perceptions of Vaping Products Among Young Adults

Purpose

This study will examine how young adults perceive new vaping products.

Participation involves taking part in a study at The Center for Tobacco Research. You will be asked to attend 3 study visits over the course of 3 weeks (1 visit/week for 3 weeks). You will be asked to bring your own preferred e-cigarette device to each study visit.

 

Could this study be right for you?

• Must be a current e-cigarette user
• Must be willing to attend 3 in-person study visits

Age Range

21 - 34 years

Official Title The ICE Study: Perceptions of E-Cigarettes and Synthetic Cooling Agents

Purpose

This study will examine the influence of synthetic cooling agents in e-cigarettes on vaping behavior and aims to find out how adding artificial cooling ingredients affects how people use a product and their exposure to harmful chemicals.

Your participation in this study will last for 4 sessions, 1 session per week for 4 weeks.

 

 

Could this study be right for you?

• Must be a current e-cigarette user
• Must be willing to attend four in-person study sessions

Age Range

21 - 29 years

Official Title AN OBSERVATIONAL, LONG-TERM SAFETY STUDY OF TZIELD® (TEPLIZUMAB-MZWV) IN PATIENTS WITH STAGE 2 TYPE 1 DIABETES

Purpose

The objective of the study is to test the safety and efficacy of TZIELD over the course of 10 years in patients with Stage 2, Type 1 Diabetes, as well as the prevention of Stage 3, Type 1 Diabetes. 

Could this study be right for you?

Inclusion Criteria:

TZIELD-Exposed Cohort
1. Patients in the US diagnosed with Stage 2 T1D who are planned to initiate TZIELD treatment according to the currently approved label or who have initiated TZIELD treatment within 6 months prior to enrollment:
− Day 1: 65 μg/m²
− Day 2: 125 μg/m²
− Day 3: 250 μg/m²
− Day 4: 500 μg/m²
− Days 5 through 14: 1,030 μg/m² per day
− Cumulative dose is approximately 11,240 μg/m²

2. Appropriate written informed consent/assent as applicable for the age of the patient

TZIELD-Unexposed Cohort
1. Patients in the US diagnosed with Stage 2 T1D but who are not treated with TZIELD
2. Appropriate written informed consent/assent as applicable for the age of the patient

Exclusion Criteria:
1. Patients who initiated TZIELD treatment more than 6 months prior to enrollment
2. Patients who had participated in a previous clinical trial for TZIELD
3. Patients in an ongoing clinical trial of an investigational product or who had ended participation within 6 months prior to study enrollment; patients participating in other observational studies may be enrolled.

Age Range

18 - 70 years

Official Title A Phase 2/3 multicenter, double blinded, randomized, dose-conversion, active control study examining the efficacy and safety of Armour Thyroid compared to synthetic T4 for the treatment of adults with primary hypothyroidism

Purpose

The purpose of this study is to evaluate if Armour Thyroid is safe and effective in the treatment of hypothyroidism.

 

You will participate in this study for up to 90 weeks. The study will be conducted in 3 treatment periods plus a Screening and Follow-up period: • Screening period (up to 28 days)– the dose of Armour Thyroid will be adjusted as needed to ensure your Hypothyroidism is well controlled  • Follow-up period (approximately 35 days following the last dose of study drug)  

Could this study be right for you?

• Were diagnosed with hypothyroidism at least 12 months ago

• Have been on a stable dose of T4 (like levothyroxine or Synthroid) for at least 3 months

• Have a recent TSH level between 0.45–4.12 mIU/L

• Are between BMI 18 and 40

• Are not pregnant or breastfeeding and use birth control if needed

• Are not allergic to thyroid meds or pork products

• Have no recent drug/alcohol abuse or severe liver/kidney disease

• Are not in another clinical trial

• Take no more than 200 mcg of T4 daily

Age Range

18 - 75 years

Official Title Brief Digitally Enhanced Intervention for Managing Emotional Pain and Reducing Alcohol Use during Medication for OUD (Phase Two)

Purpose

This study is being done to further examine and improve how a brief clinical treatment intervention may reduce alcohol use among patients engaged in medication for opioid use disorder (MOUD) treatment.

The length of the study is approximately 10 weeks and will include two on-campus lab visits at Ohio State's Medical Campus, daily surveys via a smartphone app (surveys 3 times a day for ~21 days), three treatment sessions (completed online or in-person), and follow-up questionnaires (completed online). The total time commitment of the study is 11 hours and 6 minutes.

Could this study be right for you?

Inclusion Criteria:

• engaged in MOUD treatment (for at least one month)
• alcohol consumption (within the past 12 months)
• age 18 or older
• access to a smart phone

(partial list of inclusion criteria)

Exclusion Criteria:

• diagnosis of psychosis or bipolar I
• currently pregnant (positive pregnancy test)

(partial list of exclusion criteria)

Age Range

18 years and up

Official Title Establishing Reference Values and Clinical Decision Points for Quantitative Videofluoroscopic Measures of Swallowing

Purpose

This study will help create healthy reference values clinicians can use to evaluate adult patients of all ages and is sponsored by the National Institute on Aging.  During this study, we will perform an x-ray swallowing exam and breathing tests with persons who do not have a personal history of swallowing problems or any disorders that could contribute to a swallowing problem.  Study participation will consist of a screening meeting (approximately 15 minutes) via phone call, video chat, or email to verify eligibility, and one in-person visit to our laboratory (approximately 1 hour).

Could this study be right for you?

• If you are biologically female and of child-bearing age (<63), you must not be pregnant or breastfeeding.
• No personal history of surgery or radiation therapy to the head or neck (mouth, jaw, neck, brain, nose, face, thyroid, throat, or voice box) other than having your tonsils, adenoids, or teeth removed.
• No personal history of cancer involving structures of the head, neck, spine, respiratory, or lymphatic system.
• No personal history of stroke or other progressive nerve disease.
• No current diagnosis or personal history of Chronic Obstructive Pulmonary Disease (COPD).
• No known allergies to barium.

Age Range

54 - 89 years

Official Title The Development of Semantic Organization

Purpose

We are currently in the process of conducting a 5-year National Institutes of Health-funded longitudinal study on semantic and language development, specifically focusing on how children learn new words and understand their meanings. Our goal is to not only examine language learning but also how these processes evolve as children grow.

In this study, we will follow two hundred 4-year-old junior scientists as they participate in fun, interactive word-learning and language activities. Over the course of the study, participants will visit our lab twice a year, each lasting around 60-90 minutes (including breaks), to engage in a series of playful games with a research assistant designed to explore how children comprehend and retain new vocabulary. Additionally, your child will have the opportunity to wear a LENA recorder—a small, wearable device that tracks the number of words your child hears throughout the day, similar to a Fitbit but for words!

 

Could this study be right for you?

• Child must be monolingual
• Not born premature
• No developmental delays
• Can give a verbal response
• Normal to corrected vision

Age Range

4 - 4 years

Official Title Neural Biomarkers of Sensory Symptoms in Autism

Purpose

The purpose of this study is to understand sensory processing in children on the autism spectrum, Using EEG, we will look at brainwaves while children play different computer games. We will also have children play some paper-pencil games during their visit to our lab. We hope to better understand sensory experiences and support autistic people in ways that celebrate their unique strengths.

Could this study be right for you?

Inclusion criteria for the autism group are

• Diagnosis of autism from a licensed psychologist based on the Autism Diagnostic Interview-Revised or the Autism Diagnostic Observation Schedule (ADOS),
• Aged 8 - 12 years old
• Normal/corrected vision/hearing, and IQ > 65. 19 Children taking stimulant medications will be included in the study but will be required to be off medication for 24 (for short-acting preparations) to 48 h (long-acting preparations) prior to the visit 

Inclusion criteria for the age-matched TD control group include:

• No concerns/diagnoses of any neurodevelopmental, learning, or mental health conditions 

Age Range

8 - 12 years

Official Title A Multi-center, Phase 1/2a, First-in-human (FIH) Study Investigating the Safety, Tolerability, and Efficacy of AMT-260 in Adults with Unilateral Refractory Mesial Temporal Lobe Epilepsy (MTLE) Administered via Magnetic Resonance Imaging (MRI)-guided Convection-enhanced Delivery (CED)

Purpose

You are being invited to participate in a study about mesial temporal lobe epilepsy (MTLE) on only 1 side (unilateral) of the brain that has not responded to medication (refractory).

The study will test AMT-260, which is a new gene therapy under investigation for use in treating people like you with MTLE. It is not yet approved as a drug for treating MTLE. It can only be used in a study like this one. This is the first time this gene therapy will be used in humans. It has previously been studied in animals.

AMT-260 is a gene therapy designed to reduce the electrical signals between nerve cells (neurons) in the parts of your brain where nerve cells are abnormally connected. This reduces the extra electrical signals that happen at the same time and is intended to reduce your seizure activity.

The overall goals of this study are:

• To observe whether participants have any side effects from AMT-260 or from the procedure to deliver AMT-260 into the brain and how well participants tolerate any side effects that may occur.
• To measure if participants have changes in:
  • frequency of their seizures
  • how their seizures affect their life
  • how the human body takes up and removes AMT-260
• To find the best dose of AMT-260 for future participants to ensure clinical benefit with minimal or no side effects.

Could this study be right for you?

Adult, 18-65 years of age, inclusive, capable of giving informed consent.
Written informed consent is given freely after the nature of the study has been explained to the participant and the completion of data disclosure.
Willingness to undergo necessary surgical procedures.
Diagnosis of unilateral refractory MTLE for ≥360 days, confirmed by an Epilepsy Monitoring Unit.

Additional Eligibility Criteria to be assessed by neurosurgery team, and as described in the study protocol.

Age Range

18 - 65 years

Official Title IMPROVE-AD Trial: IMPRoving Outcomes in Vascular DisEase – Aortic Dissection

Purpose

The goal of this study is to figure out the best way to treat type aortic dissection. An aortic dissection is a tear in the wall of the aorta. The aorta is a big blood vessel that carries blood from your heart to the rest of your body. Individuals with this problem usually get medicine or a special repair procedure. This procedure is called thoracic endovascular aortic repair (TEVAR). TEVAR is a procedure where a metal tube (called a stent), is inserted in the damaged part of the aorta. The study is being done to figure out which treatment works better. The results of the study may help to prevent future problems with the aorta or other health issues. 

 

Could this study be right for you?

Inclusion:

• Age > 21 years
• Stanford type B aortic dissection not involving the aorta at or proximal to the innominate artery, without rupture and/or malperfusion (renal, mesenteric, or extremity)
• Acuity: within 48 hours – 6 weeks of index admission

Exclusion criteria:

• Ongoing systemic infection
• Pregnant or planning to become pregnant in the next 3 months
• Life expectancy related to non-aortic conditions < 2 years
• Prior surgery for aortic dissection

Age Range

21 years and up